[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …
affecting around 46 million people worldwide but few treatments are currently available. The …
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …
late-onset Alzheimer disease (AD), with the APOE* ε 4 allele conferring an increased risk …
Sex differences in Alzheimer disease—the gateway to precision medicine
Alzheimer disease (AD) is characterized by wide heterogeneity in cognitive and behavioural
syndromes, risk factors and pathophysiological mechanisms. Addressing this phenotypic …
syndromes, risk factors and pathophysiological mechanisms. Addressing this phenotypic …
Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
Introduction We estimated the age-specific duration of the preclinical, prodromal, and
dementia stages of Alzheimer's disease (AD) and the influence of sex, setting …
dementia stages of Alzheimer's disease (AD) and the influence of sex, setting …
Association of factors with elevated amyloid burden in clinically normal older individuals
Importance The Anti-Amyloid Treatment in Asymptomatic Alzheimer disease (A4) Study is an
ongoing prevention trial in clinically normal older individuals with evidence of elevated brain …
ongoing prevention trial in clinically normal older individuals with evidence of elevated brain …
Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults
Importance Mounting evidence suggests that sex differences exist in the pathologic
trajectory of Alzheimer disease. Previous literature shows elevated levels of cerebrospinal …
trajectory of Alzheimer disease. Previous literature shows elevated levels of cerebrospinal …
Alzheimer's disease: a brief history of immunotherapies targeting amyloid β
ACS Vogt, GT Jennings, MO Mohsen, M Vogel… - International journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) is the most common form of dementia and may contribute to 60–
70% of cases. Worldwide, around 50 million people suffer from dementia and the prediction …
70% of cases. Worldwide, around 50 million people suffer from dementia and the prediction …
Endogenous and exogenous estrogen exposures: how women's reproductive health can drive brain aging and inform Alzheimer's prevention
S Jett, N Malviya, E Schelbaum, G Jang… - Frontiers in Aging …, 2022 - frontiersin.org
After advanced age, female sex is the major risk factor for late-onset Alzheimer's disease
(AD), the most common cause of dementia affecting over 24 million people worldwide. The …
(AD), the most common cause of dementia affecting over 24 million people worldwide. The …
Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression
Studies have shown that women on the Alzheimer's disease (AD) continuum have more
pathological tau in the brain and cerebrospinal fluid (CSF), than men. Some studies have …
pathological tau in the brain and cerebrospinal fluid (CSF), than men. Some studies have …
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
CR Jack Jr, HJ Wiste, H Botha, SD Weigand… - Brain, 2019 - academic.oup.com
Large phenotypically diverse research cohorts with both amyloid and tau PET have only
recently come into existence. Our objective was to determine relationships between the …
recently come into existence. Our objective was to determine relationships between the …